Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...
A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...
Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
A 52-year-old man has knocked his decade-long cocaine addiction on the head after receiving weight-loss injections. The jab ...
American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic anterior optic neuropathy (NAION).
The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail ...
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 ... of semaglutide were comparable, while around a third of patients treated with 7.2mg achieved more than 25% weight loss.